|
|
|
Volumn 251, Issue 2, 1989, Pages 557-562
|
|
Characterization of an 125I-labeled thromboxane A2/prostaglandin H2 receptor agonist
a
a
a
a
a
a
a
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID;
7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID;
7 [3 [3 HYDROXY 4 (4 IODOPHENOXY) 1 BUTENYL] 7 OXABICYCLO[2.2.1]HEPTAN 2 YL] 5 HEPTENOIC ACID;
7 [3 [4 (3 AMINOPHENOXY) 3 HYDROXY 1 BUTENYL] 7 OXABICYCLO[2.2.1]HEPTAN 2 YL] 5 HEPTENOIC ACID;
9 (4 CHLOROBENZYL) 6 FLUORO 1,2,3,4 TETRAHYDROCARBAZOLE 1 ACETIC ACID;
9,11 EPITHIO 11,12 METHANOTHROMBOXANE A2;
PROSTAGLANDIN RECEPTOR;
RADIOISOTOPE;
15 HYDROXY 11 ALPHA,9 ALPHA (EPOXYMETHANO)PROSTA 5,13 DIENOIC ACID;
7 (3 (3 HYDROXY 4 (4' IODOPHENOXY) 1 BUTENYL) 7 OXABICYCLO(2.2.1)HEPTAN 2 YL) 5 HEPTENOIC ACID;
7-(3-(3-HYDROXY-4-(4'-IODOPHENOXY)-1-BUTENYL)-7-OXABICYCLO(2.2.1)HEPTAN-2-YL)-5-HEPTENOIC ACID;
BICYCLO COMPOUND;
BRIDGED COMPOUND;
DIAGNOSTIC AGENT;
PROSTAGLANDIN ENDOPEROXIDE;
PROSTAGLANDIN H2 RECEPTOR;
RADIOACTIVE IODINE;
THROMBOXANE RECEPTOR;
UNSATURATED FATTY ACID;
ANIMAL CELL;
ARTICLE;
BINDING COMPETITION;
BINDING KINETICS;
CALCIUM CELL LEVEL;
DOG;
DRUG CONCENTRATION;
DRUG SYNTHESIS;
HUMAN;
HUMAN CELL;
NONHUMAN;
NORMAL HUMAN;
PRIORITY JOURNAL;
SAPHENOUS VEIN;
THROMBOCYTE AGGREGATION;
THROMBOCYTE SHAPE;
VASOCONSTRICTION;
VOLUNTEER;
DRUG EFFECT;
METABOLISM;
RADIOASSAY;
15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID;
BICYCLO COMPOUNDS;
BRIDGED COMPOUNDS;
FATTY ACIDS, UNSATURATED;
HUMAN;
IODINE RADIOISOTOPES;
PLATELET AGGREGATION;
PROSTAGLANDIN ENDOPEROXIDES, SYNTHETIC;
RADIOLIGAND ASSAY;
RECEPTORS, PROSTAGLANDIN;
RECEPTORS, THROMBOXANE;
SUPPORT, NON-U.S. GOV'T;
SUPPORT, U.S. GOV'T, P.H.S.;
|
|
EID: 0024473320
PISSN: 00223565
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (97)
|
|
References (0)
|
